Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) (ROCITP2)
Prospective Study Assessing the Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism
Pregnant women with a prior history of venous thromboembolism (VTE) are at increased risk of recurrent VTE. Current guidelines assessing the role of prophylaxis in pregnant women with prior VTE are based primarily on expert opinion and the optimal clinical management strategy remains unclear.
This multicentre, prospective cohort study aims to test the following hypotheses:
- Antepartum prophylaxis with fixed-dose low molecular-weight heparin (LMWH) is safe, convenient and associated with an acceptably low risk of recurrent VTE in women with a single prior episode of VTE that was either unprovoked or associated with a minor transient risk factor. (Moderate risk cohort)
- Withholding antepartum prophylaxis is safe (recurrence risk <1%) in pregnant women with a single prior episode of VTE provoked by a major transient risk factor. (Low risk cohort)
All study patients will receive 6 weeks of postpartum prophylaxis.
調査の概要
状態
状態
研究の種類
研究の種類
入学 (予想される)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Shannon M Bates, MD
- 電話番号:73928 905-521-2100
- メール:batesm@mcmaster.ca
研究連絡先のバックアップ
- 名前:Nancy Lloyd, MSc
- 電話番号:33269 905-522-1155
- メール:lloydn@mcmaster.ca
研究場所
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 4A6
- St. Joseph's Healthcare Hamilton
-
Hamilton、Ontario、カナダ、L8N 3Z5
- McMaster University Medical Centre
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Confirmed pregnancy (positive serum or urine)
- At least 18 years of age
- History of one prior episode of VTE consisting of DVT (diagnosed by compression ultrasonography [CUS] or venography) and/or PE (diagnosed by ventilation-perfusion [V/Q] lung scintigraphy, computed tomographic pulmonary angiography [CTPA], or traditional pulmonary angiography)
Exclusion Criteria:
- Ongoing need for therapeutic anticoagulation for prevention or treatment of cardioembolic stroke
- Known high-risk thrombophilia (specifically antithrombin deficiency, protein S deficiency, protein C deficiency, homozygosity for the factor V Leiden or prothrombin G20210A mutations, antiphospholipid antibody or compound abnormalities)
- VTE within 3 months of the current pregnancy
- Clinical risk factor for initial episode of VTE, if present, not resolved (excluding pregnancy)
- Known contraindication to anticoagulation (including active, uncontrolled bleeding or major bleed within the previous 4 weeks)
- For patients with prior unprovoked VTE, contraindication to LMWH (including allergy, HIT, impaired renal function, osteoporosis)
- Geographic or social factors precluding follow-up
- Inability or unwillingness to provide informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Prior VTE minor transient risk factor
Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
|
|
Prior VTE major transient risk factor
Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Symptomatic venous thromboembolism
時間枠:antepartum period (expected average 7 months)
|
Symptomatic objectively confirmed recurrent VTE, including proximal DVT, non-fatal PE, and fatal PE during antepartum period
|
antepartum period (expected average 7 months)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Symptomatic recurrent venous thromboembolism
時間枠:antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic recurrent VTE antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
|
Symptomatic recurrent pulmonary embolism
時間枠:antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic objectively confirmed recurrent PE antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
|
Thrombocytopenia or heparin-induced thrombocytopenia (HIT)
時間枠:antepartum period (expected average 7 months)
|
Thrombocytopenia or HIT during antepartum period
|
antepartum period (expected average 7 months)
|
|
Symptomatic osteoporosis
時間枠:antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic osteoporosis antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
|
Other complications
時間枠:antepartum (expected average 7 months) and within first 3 months postpartum
|
Other complications sufficient to stop treatment (e.g., local and systemic reactions) antepartum and within first 3 months postpartum
|
antepartum (expected average 7 months) and within first 3 months postpartum
|
|
Pregnancy complications and outcomes
時間枠:antepartum period (expected average 7 months)
|
Pregnancy complications and outcomes including fetal death, pre-eclampsia, toxemia, intrauterine growth restriction, prematurity during antepartum period
|
antepartum period (expected average 7 months)
|
|
Fetal anomalies
時間枠:antepartum (expected average 7 months) and during first 3 months postpartum
|
Fetal anomalies
|
antepartum (expected average 7 months) and during first 3 months postpartum
|
|
Major and minor bleeding
時間枠:antepartum (expected average 7 months)
|
Major and minor bleeding
|
antepartum (expected average 7 months)
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Shannon M Bates, MD、McMaster University Medical Centre
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (予想される)
一次修了
研究の完了 (予想される)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (見積もり)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- HHS130511
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。